Bandeau haut
L'INCa et la fondation ARC participent à un appel à projets européen Transcan-2 JTC-2015. Le thème est "immunologie et immunothérapie des cancers: renforcement des aspects translationnels".
Extrait de l'appel à projets:
In the past few years, the increased understanding of the human immune system, of the basic mechanisms involved in the recognition of cancer cells by innate and acquired immune cells and of escape pathways put in place by cancer and its microenvironment have paved the way to the development of innovative immunotherapeutic strategies.
In the context of Translational Research, this topic will comprise three specific aims which concur to the possible clinical applications. Proposals will have to cover at least one of the specific areas listed under each aim below. Projects should be built from a solid and established hypothesis and should be relevant with regards to the possible improvements in clinical practices.
Aim 1: Identification and validation of shared or personalized mutated human tumor antigenic targets.
• Application of “omics” approaches for the identification and validation of immunogenic mutated epitopes in primary and/or metastatic, synchronous as well as metachronous tumor lesions.
• Development of ex-vivo and/or in vivo models to be established starting from patients samples for screening immunogenicity and efficacy of personalized vaccines targeting mutated epitopes.
Aim 2: Development of new and combined immunotherapeutic strategies for cancer patients.
• Development of new vaccine formulations for active immunotherapies, including DNA, RNA vaccines, viral vectors as well as heterologous prime-boost combinations.
• Development of combined therapeutic approaches including the above antigen-targeting immunotherapies with immune compensating therapies based on irradiation, metronomic chemotherapy and/or anti-immune checkpoint inhibitors and/or adoptive T cell therapies with genetically engineered T cells.
• Development of interventions directed to counteract the role of tumor microenvironment in immune escape and immune evasion.
Aim 3: Translational research for clinical application of cancer immunotherapy.
• Identification of intratumoral and/or peripheral blood biomarkers predictive of the efficacy of cancer immunotherapies and establishment of bioassays to monitor the efficacy of cancer immunotherapy.
• Implementation of new approaches for patient stratification for clinical trials.
• Design and performance of Phase I and Phase II clinical trials for combined cancer immunotherapy strategies.
• Toxicity: understanding & anticipating toxicity problems linked to cancer immunotherapy
Date limite de candidature: 2 février 2016.
